A herbicide compound, 3,4-D, was successfully intercalated into the layer of ZAL for the formation of a new organic inorganic hybrid nanocomposite, N3,4-D, which shows a potential to be used as a controlled-release formulation in agrochemicals.
The release of 4-amino salicylic acid anions from nanocomposite was found to occur in a controlled manner, so the resulting material is suitable for a controlled-release formulation.
Although a controlled-release formulation is available [ 12], patients transferred to it from the immediate-release (IR) levodopa formulation have not consistently experienced significant 'off' time reduction [ 13– 17] or a predictable response [ 18– 218.
The final type of extended-release methylphenidate is the osmotic release oral system (OROS) methylphenidate, which is a controlled-release formulation that uses osmotic pressure to deliver methylphenidate at a controlled rate throughout the day (t1/2=6.4 h).
To solve these problems, we selected Eudragit (R) RS30D as a carrier and employed a solid dispersion technique to develop a controlled-release formulation of SPRC (CR-SPRC).
The first is an immediate-release formulation (Flec IR) to be taken twice a day, the second is a once-a-day controlled-release formulation (Flec CR).
Fewer adverse effects were reported during the first week of treatment in patients receiving the controlled-release formulation.
In a study evaluating the cardiac safety of the 200-mg controlled-release formulation of flecainide in the prevention of paroxysmal AF, the mean maximum QRS increase from baseline was 11.4 %, and only four patients had a maximum QRS value >100 ms under treatment [ 100].
The selective α1-adrenoceptor antagonist doxazosin in both standard formulation and gastrointestinal therapeutic system (GITS) controlled-release formulation is effective for hypertension without having a negative impact on serum lipids.
In a study evaluating the cardiac safety of 200 mg flecainide acetate controlled-release formulation for the prevention of PAF, 4 of 227 patients had a maximum QRS value >100 ms under treatment.
One study evaluated the cardiac safety of 200-mg controlled-release formulation of flecainide in the prevention of paroxysmal AF in 227 patients.
